Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The monoamine oxidase A K305M adenovirus is a research-grade gene therapy tool consisting of an adenoviral vector that delivers a mutant variant of the human monoamine oxidase A (MAO-A) enzyme. In this variant, the lysine residue at position 305 is replaced by methionine (K305M). This specific mutation renders the enzyme unable to use oxygen as an electron acceptor for reoxidation, thereby preventing the generation of reactive oxygen species (ROS), specifically hydrogen peroxide (H2O2), while maintaining some catalytic turnover through alternative electron acceptors. It is primarily used in academic research to investigate the role of MAO-A-derived oxidative stress in conditions such as age-related cardiovascular disease and bladder cancer metabolic reprogramming.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monoamine oxidase A K305M adenovirus.